Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (677)	6/7/2003 2:27:55 AM
From: Icebrg	Respond to of 2240

HIV Topical Microbicide Drug Development To Be Topic Of Cmte. Meeting HIV topical microbicide drug development will be discussed by FDA’s Antiviral Drugs Advisory Committee at its Aug. 20 meeting. The committee will consider clinical trial design issues in the development of topical microbicides for the reduction of HIV transmission. Recently, the Bill & Melinda Gates Foundation announced its support of a Phase III trial of The Population Council’s Carraguard (lambda-carrageenan), a non-contraceptive product that adheres to viral cells and may prevent herpes and HIV. "Hopefully, we’ll be able to support three or four other compounds going into Phase III trial in order to be able to get out and have an effect as soon as possible," Microsoft and foundation head Bill Gates said at the Ninth Conference on Retroviruses and Opportunistic Infections in February. Biosyn has Savvy (glyminox 1.2% vaginal gel) in Phase I/II studies for contraception and prevention of sexually transmitted diseases, including HIV. Optime Therapeutics has a liposomal microbicide cream in preclinical development for HIV and other sexually transmitted diseases. Also in preclinical development is an HIV microbicide from Idenix Pharmaceutical. Medarex is conducting research with Epicyte Pharmaceuticals into plant-derived monoclonal antibodies (Plantibodies) microbicides for HIV and other infections. Microbicide development and women’s groups have recently called for a microbicide branch to be established at the National Institutes of Health’s National Institute of Allergy & Infectious Diseases. To watch a live or archived webcast of this meeting, click the button below. To arrange for live videoconferencing or to order videotapes and CDs, email webcasthelp@elsevier.com or call 800-332-1370 ext. 7210. Posted: Friday, June 06, 2003